1 hr ago
Ageing Brain Changes May Limit Alzheimer’s Drug Delivery
A new review looked at how ageing changes the brain’s environment.
Many medicines use tiny carriers called nanoparticles to reach the brain.
The blood-brain barrier is like a protective filter that keeps many substances out.
However, getting through this filter is only the first step.
In older brains, blood vessels may become stiffer and blood flow may decrease.
The brain’s waste-removal system and immune activity can also change.
These changes may affect where nanoparticles go and how long they stay.
The researchers want medicines to be tested in older-brain conditions before they are used to develop treatments for diseases such as Alzheimer’s and Parkinson’s.
A review warns that crossing the blood-brain barrier may not be enough to deliver medicines effectively in older brains.
Ageing can stiffen blood vessels, reduce blood flow and impair the brain’s glymphatic waste-clearance system.
Chronic immune activation may affect how drug-carrying nanoparticles are distributed, retained and cleared.
The review calls for age-responsive nanoparticles and dosing strategies that account for biological rhythms.
Researchers recommend age-specific safety and performance testing before these delivery systems enter clinical use.
- Who
- Dr Rajeev Taliyan of BITS Pilani and researchers from Taipei Medical University and affiliated institutions in Taiwan authored the review.
- What
- The review examines how ageing may change the performance of nanoparticle-based drug-delivery systems in the brain.
- Where
- The review was published in Ageing Research Reviews and involved researchers from BITS Pilani and institutions in Taiwan.
- When
- The article describes it as a new review; no specific publication date is given.
- Why
- Ageing-related changes in blood vessels, waste clearance and immune activity may affect whether medicines reach their intended targets and work effectively.
Key facts
- Publication
- Ageing Research Reviews
- Lead-named researcher
- Dr Rajeev Taliyan, Neuropsychopharmacology Division, Department of Pharmacy, BITS Pilani
- Drug-delivery focus
- Nanoparticles designed to carry medicines into the brain
- Ageing effects identified
- Blood-vessel stiffening, reduced blood flow, impaired glymphatic clearance and chronic immune activation
- Proposed approach
- Age-responsive nanoparticles that react to specific biochemical signals
- Dosing consideration
- Treatment schedules that account for daily biological rhythms
- Potential relevance
- Age-related neurological conditions including Alzheimer’s disease and Parkinson’s disease
Quotes
Dr Rajeev Taliyan
Neuropsychopharmacology researcher at BITS Pilani and co-author of the review
“Crossing the blood-brain barrier is only the first step in delivering medicines to the brain. As we age, the brain undergoes several changes that can affect how a medicine reaches its target and how well it works.”
deccanchronicle.com
Sources
Related news
Blood Thinners May Slow Cognitive Decline in Alzheimer’s
How Alzheimer’s Disease May Begin In The Brain
India’s Dementia Burden Could Nearly Double by 2036
How Diabetes, High Blood Pressure and Cholesterol Affect Alzheimer’s Risk
Five Medication Combinations Older Adults Should Avoid As They Age
Neurologist Explains How Older Brains Keep Learning After 60
Taiwan minister returns from China after rare APEC trip
Why Taiwan Remains a Crucial and Sensitive Issue for China
Xi Expected to Press Trump Over Taiwan Arms Sales
South Korea, US and Japan Renew North Korea Dialogue Push
